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ABSTRACT 
Objective: Two simple, accurate and precise chromatographic methods were developed for the determination of calcium dobesilate in the presence 
of its interfering substances as its degradation product and/or impurity hydroquinone in pharmaceutical dosage forms with lidocaine 
hydrochloride alone or in combination with dexamethasone acetate. 
Methods: The first method is HPTLC-spectrodensitometric one using benzene: methanol: ethyl acetate: ammonia: sodium lauryl sulphate (7: 2.1: 2.5: 
0.1: 0.05 v/v/v/v/w) as a developing system and scanned at 220 nm. Second one is an HPLC method where the mixture was separated on an ODS-3 C18 
column with flow rate 1 ml/min and the mobile phase was phosphate buffer: acetonitrile (35:65 v/v) (adjusted to pH 3.4 with o- phosphoric acid), 
scanned at 220 nm.  
Results: The robustness of the method was determined to assess the effect of small but deliberate variation of the chromatographic conditions on 
the determination of cited drugs in a presence of interfering substances. Robustness was determined by changing the mobile phase flow rate to 0.5, 
1,and 1.5 mLmin−1, pH to 3.5, 4, and 5, and the concentration of acetonitrile in the mobile phase to 60% and 80%. The proposed methods were 
checked using laboratory-prepared mixtures and were successfully applied for the analysis of pharmaceutical formulations containing the cited 
drugs and were validated via ICH guidelines. 
Conclusion: The proposed methods could be used for the routine analysis of the cited drugs in their pharmaceutical formulation in quality control 
laboratories. 
Keywords: Calcium-dobesilate, Lidocaine hydrochloride, Dexamethasone acetate, RP-HPLC, HPTLC-spectrodensitometry.  
 
INTRODUCTION 
Anti-haemorrhoidal (Antihaemorrhoidalia) medicines are mainly 
used in symptomatic therapy, and only partially as causal therapy of 
anorectic region disease. They are used locally, mostly as a 
combination of active compounds. Dosage forms that are used are 
suppositories and ointments. Usually compounds used in this 
therapy are anesthetics, anti-inflammatory drugs, antibiotics, 
vasoconstrictors, haemostatics, anticoagulants and antihistaminics 
[1]. Calcium dobesilate (CD) [calcium 2,5-dihydroxy-
benzenesulfonate] as a cyclohexadienolic bisulphate derivative also 
known as hydroquinone sulfonic acid, decreases the microvascular 
permeability by inhibiting the histamine and bradykinin 
concentration. In that way it reduces edema, inflammation and 
bleeding from hemorrhoids. It has a protective effect on blood 
vessels. Recent studies showed CD as an anti-oxidant improving 
endothelial function [2],[3]. 
Lidocaine hydrochloride [16-methyl-11β, 17α, 21-trihydroxy-9α-
fluoropregna-1,4 diene-3,20-dione 21-acetate] inhibits the 
inflammatory process, through the anti-inflammatory function, in 
the early stage. The function of glucocorticoids is not specific 
because it decreases the inflammatory action effects no matter what 
the cause of the reaction was [1]. 
Considering the literature CD was determined by HPLC [4] or 
potentiometric titration [5] as their official methods. CD was directly 
determined in plasma, using a flow-injection biamperometric 
method [6] and HPLC method after ion-pair extraction [7]. For the 
simultaneous determination of CD and HQ a spectrophotometric 
method and a TLC-densitometric method were developed[8]. LH 
was investigated in rectal medical gel [9] and human plasma using 
high-performance liquid chromatography (HLPC) [10, 11] and LC-
MS [12], while its official methods are HPLC [4], or potentiometric 
titration [5]. DA was determined by HPLC according to the USP [4], 
or direct spectrophotometry as the BP official method [5], or by 
HPLC in cream [13], injection solutions [14] and equine serum [15]. 
DA was also determined in tablets using chemometrics- assisted 
spectrophotometry [16], in addition to capillary electrophoresis 
[17]. While for the simultaneous determination of LH, DA, CD, and 
HQ qualitatively and quantitatively an isocratic reversed phase high 
performance liquid chromatographic method was described [18], in 
addition to several new spectrophotometric methods [19],[20].  
The chemical structures of the drugs [5] were shown in Figure1. 
 
Fig. 1: The chemical structures of the proposed drugs (a) 
lidocaine hydrochloride [LH], (b) calcium dobesilate[CD], (c) 
dexamethasone acetate[DA], and (d) hydroquinone[HQ]. 
Experimental materials and methods  
-A double beam UV-visible spectrophotometer [Shimadzu, Japan] 
model UV-1601 PC, with 1 cm quartz cells, connected to an IBM-
compatible computer was used. The software was UV-PC personal 
spectroscopy software version 3.7. The spectral band width was 2 
nm with wavelength- scanning speed of 2800 nm min-1.  
- UV lamp with short wavelength 254 nm (USA).  
International Journal of Pharmacy and Pharmaceutical Sciences 
ISSN- 0975-1491               Vol 6, Issue 11, 2014 
Innovare 
Academic Sciences 
Fahmy et al. 
Int J Pharm Pharm Sci, Vol 6, Issue 11, 123-130 
 
124 
-Camag Linomat S auto sampler with Camag micro syringe (100 µl); 
CAMAG, Muttenz, Switzerland 
-Camag TLC scanner 3 densitometer model 35/N130319 equipped 
with wincats software densitometeric evaluation; CAMAG, Muttenz, 
Switzerland 
-Precoated TLC- plates (20 cm ×20 cm, 0.25 mm ALUGRAM; Nano-
SIL Silica Gel G/UV254 Macherey Nagel, Germany).  
-Glass jar for TLC with lid 22 × 25 × 10 cm 
-Source of UVB (Philips Lamp, Germany), 8 watt, with filter 
producing radiation (280-320)  
The following requirements are taken into consideration:  
• Slit dimensions: 3 mm×0.45 mm.  
• Scanning speed: 20 mm/S.  
• Spraying rate: 10 sμL−1.  
• Data resolution: 100 μm/ step.  
The RP-HPLC Analysis was performed on a chromatographic system 
Jasco LC-Net II/ADC (Japan) equipped with UV detector (UV-2070 
plus), isocratic pump (PU-2080 plus) and 4-line degasser (DG-2080-
54). A chromatographic separation was achieved by Inertsil ODS-3 
C-18, 250 x 4.6 mm, 5µ analytical columns. Data acquisition were 
made with ChromNAV software. 
Chemicals and reagents 
Pure samples 
LH was kindly supplied by Sigmatec Company, while CD and DA 
were kindly supplied by Minapharm Company, and their purity were 
found to be 100.06 ± 0.23, 100.11 ± 0.31, and 99.89 ± 0.33, 
respectively according to BP[5], Hydroquinone (Quinol) was 
supplied by Alamia Company for Chemicals and their purity were 
found to be 100.56 ± 0.64 according to USP [4].  
Market samples 
Doxiproct ointment Each 1 gram claimed to contain 20 mg of LD, and 
40 m g of CD, while Doxiproct Plus ointment Each 1 gram claimed to 
contain 20 mg of LD, 2.5 mg DA and 40 mg of CD manufactured by 
Mina Pharm under license of OM Pharma Switzerland were purchased. 
Maximum allowed content of HQ was 0.1% in ointment [18]. 
Solvents 
Methyl alcohol, benzene, ethyl acetate, sodium lauryl sulfate and 
ammonia were purchased from El-NASR Pharmaceutical Chemicals 
Co., Abu- Zaabal, Cairo, Egypt. 
Acetonitrile and potassium dihydrogen orthophosphate were HPLC 
grade and were supplied by Sigma Aldrich. 
All solvents used were of LC grade and all reagents and chemicals 
were of analytical grade. 
All calculations and samples preparation for reference material and 
pharmaceutical formulation were done regarding the salt forms.  
Standard stock solutions for TLC- spectrodensitometric method 
LH, CD, DA, and HQ [1 mg/ml] in methanol 
Standard stock and working solutions for HPLC 
LH, CD, DA, and HQ Standard stock solution; 250 µg/mL in the 
mobile phase were prepared. 
LH, CD, DA, and HQ standard working solution; 25 µg/mL in the 
mobile phase were prepared. All solutions were freshly prepared on 
the day of analysis.  
Procedures of chromatographic methods  
Construction of calibration curves 
TLC-spectrodensitometric method  
Aliquots of 2-20 µg/band of LH, DA, and HQ standard solution [1 
mg/ml] and of 8-50 µg/band of CD standard solution [1 mg/ml] 
were applied in the form of bands on TLC plate. The bond length was 
4 mm and dosage speed was 150 nL S-1, the bands were applied 12.8 
mm apart from each other and 15 mm from the bottom edge of the 
plate. Linear ascending development was performed in a 
chromatographic tank previously saturated with the mobile phase 
(benzene: methanol: ethyl acetate: ammonia: Sodium lauryl sulphate 
[7:2.1:2.5:0.1:0.05, v: v: v: w]) for 15 minutes at room temperature. 
The developed plates were air-dried and scanned at 220 nm using 
the deuterium lamp, absorbance mode at 3 mm x 0.45 mm slit 
dimension and scanning speed of 20 mm S-1. The spots were scanned 
using the following conditions:  
- Photo mode: reflection. Scanning mode: zigzag. Wavelength: 220 nm. 
- Result output: chromatogram and area under the peak (AUP).  
Calibration curves relating the optical density of each spot to the 
corresponding concentration of CD, DA, LH, and HQ were 
constructed. The regression equations were then computed for the 
studied drugs and used for determination of unknown samples. 
High performance liquid chromatographic methods  
Method (1) 
Aliquots be equivalent to 10-500 µg LH, CD, and HQ, while aliquots 
equivalent to 50-600 µg DA were accurately transferred from their 
working solutions (25 µg/ml) into four separate series of 10-ml 
volumetric flasks then completed to volume with the mobile phase. 
The samples were then chromatographed using the following 
chromatographic conditions:  
Stationary phase: Inertsil C-18, 250 x 4.6 mm, 5µ analytical column, 
mobile phase, phosphate buffer: acetonitrile [35:65 v/v], the final 
pH-value was adjusted to 3.4 ± 0.2 with O-phosphoric acid using a 
pH-meter. Flow rate 1.5 mL/ min. [isocratically at ambient 
temperature [~25 ◦C] with UV detection at 220 nm.  
Calibration curves relating the peak area ratios of CD, DA, LH, and 
HQ to that of standard [20 µg/ml] versus the corresponding 
concentrations of CD, DA, LH, and HQ [µg/ml]. The regression 
equations were computed and calculations were performed 
following the external standard technique, concentrations of 
unknown samples of CD, DA, LH, and HQ were determined using the 
obtained regression equations. Linearity curves were constructed 
and the regression equations computed.  
Method (2) 
Aliquots equivalent to 10-500 µg LH and CD, while aliquots 
equivalent to 20-500 µg HQ were accurately transferred from their 
working solutions (25 µg/ml) into three separate series of 10-ml 
volumetric flasks then completed to volume with the mobile phase. 
The samples were then chromatographed using the following 
chromatographic conditions:  
Stationary phase: Inertsil C-18, 250 x 4.6 mm, 5µ analytical column, 
mobile phase; phosphate buffer: acetonitrile [20:80, v/v], the final 
pH-value was adjusted to 3 ± 0.2 with O-phosphoric acid using a pH-
meter. Flow rate 0.5 mL/ min. [isocratically at ambient temperature 
[~25 °C] with UV detection at 210 nm.  
Calibration curves relating the peak area ratios of CD, LH, and HQ to 
that of standard [15 µg/ml] versus the corresponding 
concentrations of CD, LH, and HQ [µg/ml]. The regression equations 
were computed and calculations were performed following the 
external standard technique, concentrations of unknown samples of 
CD, LH, and HQ were determined using the obtained regression 
equations. Linearity curves were constructed and the regression 
equations computed. 
Analysis of laboratory prepared mixtures  
Laboratory prepared mixtures containing different ratios of CD, DA, LH, 
and HQ were analyzed using the suggested methods, aliquots of CD, DA, 
LH, and HQ were mixed to prepare different mixtures and were 
proceeded as mentioned under each method, the concentrations from 
the corresponding regression equations were calculated.  
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Assay of pharmaceutical formulations 
For HPTLC-spectrodensitometry 
One gram Doxiproct ointment and another one gram Doxiproct plus 
ointment were accurately weighed and transferred into two separate 
10-ml volumetric measuring flasks to be dispersed in 10 ml methanol 
by shaking for 5 min. to form a stock solution of 2 mg/ml LH and 4 
mg/ml CD for Doxiproct ointment, and also 2 mg/ml LH, 4 mg/ml CD, 
in addition to 0.0025 mg/ml DA for Doxiproct Plus ointment. 
Aliquots 5,6, and 8 µl of the prepared working solution of 
pharmaceutical preparation were applied in the form of bands on 
the TLC plates and the procedure described was followed in 
Doxiproct ointment or after spiking with 5 µg DA upon working with 
Doxiproct Plus ointment. 
For HPLC 
One gram of Doxiproct ointment was accurately weighed and 
dispersed in the mobile phase by ultrasonication for 5 minutes and 
mixing via vortex mixer before transferring to 100-ml volumetric 
flask and completed to volume to form a stock solution with 
concentration 400 µg/mL CD and 200 µg/mLLH. Then 10 mls were 
taken from the stock solution into 100-ml volumetric flask and 
completed till the mark with the mobile phase to make a working 
solution with conc. 40 µg/mLCD and 20 µg/mLLH. Aliquots 0.5,0.6, 
and 0.8 ml of the prepared working solution of pharmaceutical 
preparation were transferred into 10-ml volumetric flask and the 
procedure described was followed. 
The previous steps were repeated with Doxiproct Plus ointment to 
prepare stock solution with concentration 400 µg/mL CD, 200 
µg/mLLH, and 2.5 µg/mL DA, and then 10 mls were taken from the 
stock solution into 100-ml volumetric flask and completed till mark 
with the mobile phase to make a working solution with conc. 40 µg 
/mLCD, 20 µg/mLLH, and 0.025 µg/mL DA. Aliquots 0.5, 0.6, and 0.8 
ml of the prepared working solution of pharmaceutical preparation 
were transferred into 10-ml volumetric flask and the procedure 
described was followed after spiking with 5 µg DA. 
The procedure mentioned was adopted for the determination of the 
drug in its pharmaceutical formulation and the standard addition 
technique was applied where different known concentrations of 
pure standard LH, DA, and CD was added to the pharmaceutical 
formulation before proceeding in the previously mentioned 
methods. The percentage recoveries of the drug were calculated. 
RESULTS AND DISCUSSION 
This paper described two methods for the simultaneous 
determination of LH, DA, CD, and HQ, and a third method conducted as 
a comaparative study for the simultaneous determination of LH, CD, 
and HQ. 
HPTLC -Spectrodensitometric method 
A stability indicating assay method was developed that also 
quantifies the degradation product and/or impurity, and offers a 
simple way to quantify directly on TLC plate by measuring the 
optical density of the separated bands. The method was based on 
the difference in migration rate of the components using a 
development system,the reported system for the determination of 
CD and its degradation producy and/or impurity HQ [8] was tried 
and improved in order to resolve the mixtures either binary or 
ternary in presence of hydroquinone so the optimum system was 
composed of benzene: methanol: ethyl acetate: ammonia: sodium 
lauryl sulphate (7: 2.1: 2.5: 0.1: 0.05 v/v/v/v/w), the obtained 
chromatogram showed complete separation of the cited drugs and 
the Rf values were found to be 0.06 for CD, 0.41 for HQ, 0.54 for 
DA, and 0.71 for LH. Fig (2). To improve separation of bands, it 
was necessary to investigate the effect of different variables. 
Studying the optimum parameters for maximum separation was 
carried out as following:  
 
Fig. 2: TLC-spectrodenisitometric resolution of a lab mixture of 
CD with Rf 0.06, HQ,with Rf 0.41, DA with Rf 0.54, and LH with 
Rf 0.71. 
 
Different developing systems with different ratios were tried, but 
the problem was to obtain sharp and compact peak for CD due to 
tailing upwards and downwards in most of the developing systems, 
sharp spots and complete separation of the cited drugs was achieved 
by using the previously mentioned developing system, as lower 
methanol concentrations resulted in Rf =0.00 for CD and higher 
methanol concentrations hindered the separation of LH and DA 
resulting in nearly identical Rf values for both of them. Sodium lauryl 
sulphate was used as a surfactant to decrease the tailing in the CD 
spot. The same mobile phase without ammonia had the same Rf 
values for both HQ and DA, while ammonia changed their polarity 
resulting in different retention times. Also different scanning 
wavelengths were tested, but the best sensitivity obtained was when 
we scanned at 220 nm.  
Parameters including resolution (Rs) and peak symmetry were 
calculated. The resolution is always above one and accepted values 
for symmetry factor were obtained, as shown in Table (1-b). 
 
Table 1(b): System suitability Parameters for determination of LH, HQ, CD and DA by the proposed HPTLC spectrodensitometric method 
 CD HQ DA LH Reference value 
Rf value 0.06 0.41 0.54 0.71  
Experimental Resolution (Rs) 2.235 1.76 1.12 Rs > 1 
Tailing Factor 1 0.66 0.8 1 T≤ 2 
T = 1 for symmetric peaks 
The calibration curve were constructed by plotting the peak area versus the concentration in the range of 2-20 μg/band for LH, DA, and HQ and 8-50 
µg/band for CD, the concentrations were calculated from the corresponding regression equations.  
 
High performance liquid chromatography methods  
A simple isocratic high-performance liquid chromatography method 
was developed for the determination of cited drugs in pharmaceutical 
formulations either binary mixture of LH and CD mixture(A) or their 
ternary mixture with CD mixture (B), both mixtures in presence of its 
degradation product and/or impurity HQ mixture (B).  
The cited drugs in pure form and in pharmaceutical formulations 
were separated using a 250 mm x 4.6 mm, i.d. ODS-3 C18 analytical 
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column. ODS-3 can separate compounds with low Retention times 
[21, 22]. It had strong hydrophobic properties as it was ideally 
modified with octadecyl groups and endcapped showing excellent 
reproducibility. It was based on a purer, high surface area silica 
which was especially manufactured to provide maximium bonded 
phase coverage. No peak tailing and adsorption with nitrogen 
containing compounds as lidocaine hydrochloride (LH) due to its 
high inertness, as silanol groups were eliminated through a 
proprietary bonding endcapping technology.  The mobile phase 
consisted of phosphate buffer [pH 4]: acetonitrile [35:65 v/v] and 
the final pH was adjusted to 3.4 ± 0.2 using   o-phosphoric acid. The 
average retention times under the conditions described were 2.358 
min for LH, 3.508 min for HQ, 5.833 min for CD, and 7.150 min for 
DA. (Fig 3) One sample could be chromatographed in 5 minutes. 
Calibration graphs were obtained by plotting the peak area ratios of 
drug to that of external standard versus concentrations of CD, DA, 
LH, and HQ. 
 
Fig. 3: Liquid chromatographic separation of LH at 2.358 min, 
HQ at 3.508 min, CD at 5.833 min, and DA at 7.150 min. 
Optimization of the methods  
Effect of UV wavelength  
 The drugs CD, DA, LH and HQ were scanned by UV, individually, in a 
wavelength range of 200-400 nm and maxima for each drug was 
measured. The maxima for LH was found to be 202 nm, DA at 239 
nm, and HQ at 225 nm, whereas, for CD it showed two maxima 
which were found to be at 202 nm and 305 nm. The corresponding 
UV spectrum of, CD, DA, LH and HQ are shown in Fig 4. To optimise the 
UV maxima, various HPLC experiments were performed at various 
wavelengths starting from 210 nm to 350 nm. The best response has 
been observed at 210 nm only for binary mixture of LH and CD with its 
degradation product and/or impurity HQ as they all had absorption 
maxima from 202 nm till 225 nm, while the ternary mixture in the 
presence of DA with absorption maxima 239 nm, measuring at 220 nm 
gave better linearity ranges for the four cited drugs.  
 
Fig. 4: Zero order spectra showing a ternary mixture of CD 8 µg 
ml-1 (___) showing two maxima at 305 nm and 202 nm, DA 6 
µgml-1 (__ __ __) showing λmax at 239 nm, LH 4 µgml-1 (. -. -.) 
showing λmax at 202 nm, and HQ (----) 3 µg ml-1showing λmax 
at 225 nm. 
Effect of mobile phase composition  
The mobile phase phosphate buffer: acetonitrile (35:65 v/v)was 
chosen after several trials to reach the optimum stationary/mobile–
phase matching. Higher acetonitrile concentrations ≥70 % in the 
mobile phase caused CD and DA peaks to be superimposed, and lower 
concentration of acetonitrile in the mobile phase composition 60% 
caused the superimposition of the peaks of CD and HQ. The 
chromatographic system in this work allowed complete baseline 
separation of CD, DA, LH, and HQ as shown in Fig 3. System suitability 
parameters were tested by calculating the capacity factor, tailing 
factor, the selectivity factor and resolution Table (1-a). Upon using 
phosphate buffer [pH 4]: acetonitrile [35:65 v/v] and the final pH was 
adjusted to 3.4 ± 0.2 using o-phosphoric acid. The average retention 
times under the conditions described were 2.358±0.02 min for LH, 
3.508 ±0.01 min for HQ, 5.833±0.02 min for CD, and 7.150 ± 0.01 min 
for DA. (Fig 3) with average run time 8 minutes with satisfactory 
resolution and other system suitability parameters so it could be used 
for the analysis of ternary mixtures with CD (mixture B). as in table 1a.  
 
Table 1(a): System suitability Parameters for determination of LH, HQ, CD and DA by the proposed HPLC methods 
 Parameter 
 
 HPLC method (1)  HPLC method (2)  Reference value  
LH HQ CD DA LH HQ CD 
Retention time (tR)  2.358 3.508 5.833 7.150 3.958 5.417 7.258  
Resolution (Rs) 4.662 6.655 3.272 5.308 5.499 > 1 
Tailing factor (T) 
Symmetry 
1.25 1.37 1.10 1.16 1.33 0.99 1.13 T = 1 for a typical symmetric 
peak 
Response factor 47441 41386 26521 13546 153376 86478 289366  
HETP =  
25/NTP 
0.015 0.0084 0.0089 0.004 0.005  0.005  0.003  the smaller the value the higher 
the column efficiency 
Column efficiency (NTP) 1596 2946 2787 6138 4815 4506 6928 increases with the efficiency of 
separation 
Selectivity (α) -----  2.74 4.89 1.32 ---- 3.61 1.91 >1 
 
 
Fig. 5: Liquid chromatographic separation of LH at 3.98 min, HQ at 5.41 min, and CD at7.25 min. 
 
 
A comparative study was conducted by using a mobile phase composed 
of phosphate buffer (adjusted to pH 3 (with o-phosphoric acid): 
acetonitrile (20:80 v/v) with detection at 210 nm. The average retention 
times under the conditions described were 3.98 min for LH, 5.41 min for 
HQ, and 7.25 min for CD. The average run time 7.5 minutes within a very 
good resolution as shown in Fig 5, thus it was selected for the analysis of 
binary mixture of LH and CD with its degradation product and/or 
impurity HQ mixture (A) that were present in the pharmaceutical 
formulation Doxiproct ointment, but couldn’t be used for the ternary 
mixture with DA as its peak would superimpose with the peak of CD.  
Effect of pH 
While optimizing the mobile phase pH, different pH values of mobile 
phase 3.5, 4.0 and 5.0 were used. The resolution of the peaks didn't 
change a lot, but the retention times were increasing with increasing 
the pH. In case of pH value 3.4 the o-phosphoric acid: acetonitrile 
(35:65 v/v), the retention time were 2.358 min for LH, 3.508 min for 
HQ, 5.833 min for CD, and 7.150 min for DA within a very good 
resolution and shortest run time. Hence pH 3.4 ± 0.2 of the mobile 
phase was selected for the experimental work. 
Effect of flow rate  
For the ternary mixture of LH, CD, and DA in the presence of the 
degradation product and/or HQ while optimizing the flow rate, initially 
flow rate of 1 mL/min was used and the retention time of LH was 2.358 
min, HQ was 3.508 min, CD was 5.833, and DA was 7.150 min, so the 
whole run was made in 9 min. The respective chromatograms are shown 
in Fig3.  With an intention to reduce the retention time, the flow rate was 
increased to1.5 mL/min and the Retention time was recorded to be 1.24 
min for LH, 1.85 min for HQ, 3.12 min for CD, and 3.57 min for DA min 
and the desired result of a very low Retention time was achieved but the 
system suitability parameters were not as good as upon working with 
flow rate 1 mL/min. Hence the Flow rate of 1 mL/min was selected for 
the experimental work. 
The comparative study for the binary mixture in the presence of the 
degradation product and/or impurity HQ was conducted with flow 
rate 1 mL/min, and the retention times were 1.99 min for LH, 2.70 
min for HQ, and 3.62 min for CD. With an intention to enhance 
resolution the flow rate was chosen to be 0.5 mL/min, and the 
retention times were 3.98 min for LH, 5.41 min for HQ, and 7.25 min 
for CD. The ultimate method developed is summarized in the Table 
1(a) and the comparative study showed better system suitability 
parameters especially symmetry, but could only be applied to the 
binary mixture of LH and CD in the presence of HQ. 
Method validation 
Validation of the proposed methods was assessed according to ICH 
recommendations[21]. 
Linearity and range 
The linearity of the proposed methods was evaluated by processing 
the different calibration curves on three different days.  
The calibration curves were constructed within concentration 
ranges that were selected on the basis of the anticipated drugs 
concentration during the assay of the dosage form. Each 
concentration was repeated three times. The linear regression 
equations were summarized in Table 2. The corresponding 
concentration ranges, calibration equations and other statistical 
parameters for all methods were listed in Table 3.  
 
Table 2: linearity studies and regression equations of the proposed methods 
Drug Method Regression equation Correlation coefficient (r) 
CD HPTLC-densitometry ya = 79.739x + 262.68 0.9997 
HPLC yb = 0.0406x + 0.048 0.9999 
HPLC (2) yb = 0.0613x + 0.0781 0.9999 
LH HPTLC-densitometry ya = 1169.2x + 1533.1 0.9997 
HPLC yb = 0.0474x + 0.078 0.9999 
HPLC (2) yb= 0.0607x + 0.0707 0.9998 
DA HPTLC-densitometry ya =1148.9x + 3218.6 0.9998 
HPLC yb = 0.047x + 0.0872 0.9999 
HQ HPTLC-densitometry ya = 1163.8x + 10128 0.9998 
HPLC yb = 0.0511x - 0.0125 0.9999 
HPLC (2) yb= 0.0697x + 0.0822 0.9999 
Where ya is the peak area and yb is the peak area ratio, x is the concentration of the mentioned drug 
 
Table 3: Assay parameters and method validation obtained by applying the proposed methods for determination of calcium dobesilate, 
lidocaine hydrochloride, dexamethasone acetate and hydroquinone in mixtures: 
 HPTLC-densitometry HPLC HPLC (2) 
Drug name LH CD DA HQ LH CD DA HQ LH CD HQ 






















Slope 1169.2 79.739 1148.9 1163.8 0.0474 0.0406 0.047 0.0511 0.0607 0.0613 0.0697 
Intercept 1533.1 262.78 3218.6 10128 0.078 0.048 0.0872 0.0125 0.0707 0.0781 0.0822 
























0.9997 0.9997 0.9998 0.9998 0.9999 0.9999 0.9999 0.9999 0.9998 0.9999 0.9999 
**RSD % a 0.697342 1.434886 1.217849 0.342 0.130 0.210 0.257 0.490 0.373 0.868 0.175 
**RSD% b 0.969613 1.560017 1.469259 0.611 0.742 0.281 0.300 0.684 0.521 0.931 0.568 
**RSD% a,**RSD% b: a The intra-day precision (n = 3), average of three different concentrations repeated three times within day. b The inter-day 
precision (n = 3), average of three different concentrations repeated three times in three successive day. 
 
Accuracy 
To study the accuracy of the proposed methods, procedures under 
linearity for the drugs were repeated three times for the 
determination of six different concentrations of pure LH, DA, CD and 
HQ. The accuracy expressed as percentage recoveries was shown in 
Table 3. The standard addition technique presented in Table 5 
showed no interference of pharmaceutical excipients. Good accuracy 
of the developed methods was indicated by the obtained results.  
Fahmy et al. 




The intra-day and inter-day precision of the proposed methods were 
determined by the analysis of three different concentration of the 
proposed drugs, within the linearity range, by three replicate 
analysis of three pure samples of the drugs on a single day and on 
three consecutive days, the results were illustrated in table 3. 
Selectivity  
Selectivity was ascertained by analyzing different laboratory 
prepared mixtures containing the drugs in different ratios within the 
linearity range. The RSD showed good percentage recoveries with 
the lowest standard deviation among the other methods. 
Satisfactory results were shown in table 4. 
Statistical analysis 
Table 6. shows statistical comparison of the results obtained by the 
proposed methods and official methods [5] The calculated t and F 
values were less than the theoretical ones indicating that there was 
no significant difference between the proposed and the official 
methods with respect to accuracy and precision. One-way ANOVA 
was applied for the purpose of comparison of developed methods; 
Table 7. shows that there was no significant difference between 
them for the determination of LH, DA,CD, HQ. 
Robustness 
Results from robustness testing were listed in Table 8 that resulted 
from changing the mobile phase composition and the flow rate of the 
solvent system. 
 
Table 4: Determination of CD, LH, HQ and DA by the proposed methods in laboratory prepared mixtures: 
RATIO HPTLC-densitometry HPLC HPLC (2)** 
CD: HQ: 
DA: LH 
CD HQ DA LH CD LH HQ DA CD LH HQ 




























































4:2:0.25:0* 100.58 ± 
0.96 





































*The ratio of the lab mixture present in the pharmaceutical formulation after the addition of 5 µg DA. ** Lab mixtures containing LH, CD, and HQ in 
the same ratio as the mentioned lab mixtures but without DA. 
 
Table 5: Determination of CD, LH, and DA in pharmaceutical dosage form by the proposed methods 
   CD Std Add LH Std Add DA Std Add 
Found% ± S. D R% ± S. D Found% ± S. D R% ± S. D Found%± S. D R% ± S. D 
HPTLC-
spectrodensitometry 
Doxiproct 100.21 ± 0.55  99.02 ± 1.05  98.65 ± 0.82  99.60 ± 0.93 -----  ------  
Doxiproct Plus* 100.62 ± 0.34 100.58 ± 1.23 100.51 ± 1.23 99.77± 0.70  100.02 ± 0.71 101.01 ± 
0.74 
HPLC Doxiproct 99.83 ± 0.78 100.00 ± 0.11 99.95 ± 0.70  100.39 ± 0.44  -----  ------  
Doxiproct Plus*  100.07 ± 0.34 99.95 ± 0.90   100.07 ± 0.73 99.47 ± 0.74  100.41 ± 0.49   100.42 ± 
0.85 
HPLC (2) Doxiproct  99.65 ± 0.65  99.75 ± 0.97  100.01 ± 0.52 100.59 ± 0.19 -----  ----  
*Doxiproct Plus mentioned aliquots of working solution are spiked with 5 µg DA. 
 
Table 6: Statistical comparison between results obtained by the proposed methods and the official methods for the determination of LH, 
CD and DA in pure powder form: 
















































99.61 99.54 99.99 100.2
3 
S. D. 0.87 0.94 0.91 1.66 0.79 1.14 1.21 1.15 1.70 1.76 1.33 0.89 1.68 1.03 1.56 



































3.68 ------ 2.09 2.36 ------ 2.17 2.34 
 








1.13 ------ 0.47 0.64 ------ 0.23 0.65 
 
0.47 ------ 0.13 0.72 
 
0.85 
BP (a) is a potentiometric titrimetric method and BP (b)is a spectrophotometric method USP (c) is a direct titrimetric method, * Figures in parenthesis 
are the corresponding tabulated values at P=0.05. 
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Table 7: Results of ANOVA (single factor) for comparison of the proposed methods and the reported official methods for determination of 
LH, CD, DA, ad HQ in pharmaceutical dosage form 
 Source of Variation Sum of squares Degree of freedom Mean square F P-value F crit 
LH Between Groups 2.035454 3 0.678485 0.297162 0.827003 3.098391 
Within Groups 45.66438 20 2.283219    
Total 47.69983 23     
CD Between Groups 3.31671 3 1.10557 0.840819 0.487482 3.098391 
Within Groups 26.29744 20 1.314872    
Total 29.61415 23     
DA Between Groups 0.368607 2 0.184304 0.161851 0.852033 3.68232 
Within Groups 17.08084 15 1.138723    
Total 17.44945 17     
HQ Between Groups 1.865775 3 0.621925 0.348385 0.790702 3.098391 
Within Groups 35.70329 20 1.785165    
Total 37.56907 23         
 
Table 8: Results from testing of the robustness of the method by changing the composition of the mobile phase. (The concentration of the 
solution analyzed was 25 µg/mL) 
Mobile phase composition 
(acetonitrile–phosphate buffer) 
Flow rate   
mL/min 
Rt Resolution 
Original Used Level LH HQ CD DA LH HQ CD DA 
65:35 60:40 -5 0.5  6.408 8.008 10.642 12.317 1.482 2.272 1.716 
1   2.842 4.250 4.733 6.658 3.420 0.874 4.530 
1.5  1.459 2.800 3.125 4.125 ---- ----- ---- 
65:35 0 1   2.358 3.508 5.833 7.150 4.662 6.655 2.284 
1.5  1.242 1.85 3.125 3.75 3.657 5.718 2.391 
70:30 +5 1  2.825 4.150 5.575 5.917 3.134 ----- ----- 
1.5  1.975 2.767 3.708 3.825 2.743 ---- ------ 
 
CONCLUSION  
The advantages of HPTLC-densitometric method were that several 
samples could be run simultaneously using a small quantity of 
mobile phase unlike HPLC, thus lowering analysis time and cost per 
analysis and providing high sensitivity and selectivity.  
The HPLC methods had a relatively short run time (<8 min) for the 
first method and (<8 min) for the second method that allowed 
quantifying a large number of samples in routine and quality control 
analysis. In the proposed method, there were no additional 
extraction or separation procedures to extract the drugs from the 
formulation excipient matrix thereby decreasing the error in 
quantitation. Moreover, the suggested HPLC methods were more 
sensitive and had a wider range of linearity than the proposed 
densitometry TLC method. Although there were recent 
spectrophotometric methods but in HPLC the mobile phase is easy 
to prepare. Since these methods are simple, specific, rapid, precise 
and accurate, they may be successfully and conveniently adopted for 
routine quality control analysis of cited drugs in bulk and 
pharmaceutical dosage forms. 
According to the validation parameters, we concluded that the 
proposed methods were sensitive and selective, and could be used 
for routine analysis of the cited drugs and in its available dosage 
forms as well as quantitative determination of the degradation 
product and/or impurity hydroquinone in order to determine the 
extent of degradation or contamination with its precursor. 
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